Attgeno AB, home of Supernitro, is a Swedish clinical stage pharmaceutical company founded by a research group at the Karolinska Institute, Stockholm, to develop and bring to market new nitric oxide (NO)-donating technology and products. Our first drug candidate, Supernitro, is based on a novel principle developed by Attgeno and is intended to reverse life-threatening high blood pressure in the lungs (acute pulmonary hypertension, aPH).
Company Details
- Employees
- 8
- Founded
- 2006
- Address
- Fogdevreten 2a, Solna,17165,sweden
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://attgeno.com/
- Keywords
- Biomedicine.
- HQ
- Solna
Attgeno Questions
Attgeno's website is https://attgeno.com/
Attgeno's LinkedIn profile is https://se.linkedin.com/company/attgeno
Attgeno has
8 employees.
View email and phone details for 8
employees at Attgeno.
Attgeno's industry is
Pharmaceutical Manufacturing
Attgeno's top competitors are
Affibody Ab,
Redwood Pharma Ab (Publ.),
Farmantra S.l.,
Octapharma Sweden,
Atrogi,
Gesynta Pharma Ab,
Renapharma Ab,
Northx Biologics,
Diamyd Medical,
Empros Pharma.
Attgeno's categories are Pharmaceutical Manufacturing
Attgeno's founding year is 2006
